** Shares of medtech firm Lensar LNSR.O fall 3.7% to $14.27
** LNSR has agreed to be acquired by Swiss eyecare firm Alcon ALCC.S for $14/shr, totaling around $356 million
** Deal represents a 5.6% discount to LNSR's last close
** U.S.-listed shares of Alcon ALC.N up 1.8% at $92.18
** Alcon may pay Lensar an additional $2.75/shr, totaling up to $430 million, if certain procedure targets are met
** Deal is expected to close in mid-to-late 2025
** LNSR up more than four-fold and U.S.-listed shares of ALC up 7.9% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。